OncoTricks

Liquid biopsy, Oct 8, 2026

A blood test for cancer: ask the question first

If you remember one thingThree different kinds of test go into the same tube. The wrong kind gives a confident answer to a question nobody asked.

A new lesion, and the team wants a target

Is there a tissue diagnosis of this lesion?
no
Biopsy firstBlood adds to tissue. It does not make the diagnosis.
yes, or biopsy is not possible
Do you need a target to choose a drug?
yes
Broad plasma panel, with tissueGuardant360 Liquid or FoundationOne Liquid CDx. A negative sends you back to tissue.
no
Treated to cure, and asking if it is gone?
yes
Residual disease testSignatera or similar, repeated samples, not one. Changes treatment in bladder cancer after cystectomy. Elsewhere it predicts relapse and no trial has shown that acting on it helps; order it with a plan for what a positive will change.
never
Shield or Galleri in a patient with cancer or symptomsThey screen healthy people

Three questions, three families

1

Which drug?

Advanced cancer. Reads hundreds of genes in the blood. No tissue needed.

Guardant360 Liquid, FoundationOne Liquid CDx, Tempus xF, Caris Assure

2

Is it still there?

After curative treatment. Follows one known cancer over time.

Signatera, Guardant Reveal, NeXT Personal, RaDaR, Oncodetect

3

Is there a cancer at all?

People with no cancer and no symptoms. Screening.

Shield, Galleri

Signatera never reports a new target. A broad panel is too shallow to call a patient clear.

Where the tube runs quiet

Lung cancer with a known driver, at progression: plasma test positive
Progression only in the brain
52%
Only outside the brain
84%
Lung, 247 patients (Aldea 2020). Melanoma with brain metastases only: 0 of 13 positive (Lee 2020). A clean plasma result with disease only in the brain means little.

Order it from clinic, not from the ward

Drawn during the admission and ordered within 14 days of discharge→Medicare dates it to the hospital stay
Drawn as an outpatient, result not needed for that visit→The laboratory bills Medicare directly

The result takes 1 to 3 weeks, so it rarely changes anything during the admission. The same rule catches a surgical specimen sent for testing within 14 days of discharge. If the result will change treatment before discharge, order it. The rule is about billing, not about care.

What changes treatment today

Changes treatmentA drug target found in advanced cancer.
ESR1 in breast cancer.
Bladder cancer after cystectomy: Signatera selects atezolizumab.
Large B-cell lymphoma: a PET-positive scan at the end of treatment.
Prognosis only, for nowAfter surgery in colorectal, lung, breast, pancreas and most other cancers.
Following response to immunotherapy.

ASCO 2026: do not use the amount of tumor DNA in blood as a stand-in for tumor burden. It is prognostic (prostate: tumor fraction above 30% carries 5.6 times the risk of death), not a measurement.

The screening family, briefly
  • Shield (Guardant): FDA approved in July 2024 for colorectal cancer screening at average risk, age 45 or older. It found 83% of colorectal cancers and 13% of advanced polyps, with 90% specificity. Stage I detection was 55% (12 of 22 cancers; the interval runs from 35 to 73%).
  • Galleri (GRAIL): reads methylation patterns for many cancers at once. Specificity 99.5%; sensitivity 17% in stage I, 40% in stage II, 77% in stage III, 90% in stage IV. When positive, 38 to 60% turned out to be cancer.
  • The randomized NHS trial of 142,250 people did not reduce stage III or IV diagnoses of 12 prespecified cancers after three annual screens (rate ratio 1.03); for stage IV alone it was 0.86 (0.74 to 1.00), not significant.
  • Galleri is not FDA approved as of October 2026. An advisory panel voted on September 23, 2026: unanimous on safety, 6 to 4 on effectiveness, 7 to 2 on benefit over risk.
Sources

Retrieved from PubMed (abstracts), FDA records, product labels and the Medicare rule itself. Items dated 2026 come from FDA and news pages read on Oct 15, 2026.

  1. Aldea M, et al. Circulating tumor DNA with isolated central nervous system progression. J Thorac Oncol 2020. doi:10.1016/j.jtho.2019.11.024
  2. Lee JH, et al. Circulating tumor DNA and intracranial melanoma. Clin Cancer Res 2020. doi:10.1158/1078-0432.CCR-19-3926
  3. CMS laboratory date of service policy. Policy. Regulation: 42 CFR 414.510
  4. Lockwood CM, et al. ASCO guideline on circulating tumor DNA. JCO Oncol Pract 2026. doi:10.1200/OP-26-00311
  5. Chung DC, et al. ECLIPSE: a cell-free DNA blood test for colorectal cancer screening. N Engl J Med 2024. doi:10.1056/NEJMoa2304714
  6. Shield provider labeling. Label
  7. Klein EA, et al. Validation of a multi-cancer early detection test. Ann Oncol 2021. doi:10.1016/j.annonc.2021.05.806
  8. Schrag D, et al. PATHFINDER. Lancet 2023. doi:10.1016/S0140-6736(23)01700-2
  9. Nabavizadeh N, et al. PATHFINDER 2. Nat Med 2026. doi:10.1038/s41591-026-04618-w
  10. Sasieni P, et al. NHS-Galleri randomized trial. N Engl J Med 2026. doi:10.1056/NEJMoa2505723